The company's product Azadine, which is a generic version of US-based Celgene Corporation's Vidaza, is used for treating MDS (Myelodysplastic Syndrome) and AML (Acute Myelogenous Leukemia), types of cancer. MDS is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal cells in the blood and/or in the bone marrow. Advanced stages of MDS may lead to AML.

Azacitidine is the only drug which has been shown to prolong overall survival duration and time to transformation into AML, increase response rate, reduce transfusion burden and improve quality of life.

Intas is manufacturing Azadine at its Ahmedabad facility, which operates in compliance with global regulatory standards like USFDA, MHRA and ANVISA.

The company has a portfolio of drugs catering to various therepeutic segments including central nervous system (CNS), cardiovascular system (CVS) and diabetes.